A study of LV009 for certain blood cancers
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests an experimental treatment called LV009 for people with certain types of blood cancers that have come back or not responded to previous treatments. The treatment targets a protein called CD19 found on cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- Your cancer (like non-Hodgkin lymphoma or acute lymphoblastic leukemia) is CD19-positive and has come back or not responded to treatment.
- You are well enough to have a life expectancy of more than 12 weeks and can perform daily activities with some help (ECOG score 0-2).
- Your blood counts, liver, kidney, and heart function are within certain limits.
- You have not had high-dose steroids or strong immune-suppressing drugs within 5 days before the treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy that targets two proteins (CD19 and CD20) found on certain lymphoma cells. It is designed for patients whose lymphoma has not responded to or has returned after previous treatment, and who cannot or choose not to receive standard CAR-T therapy.
This trial tests a new cell therapy called UTAA09 for people with certain types of lymphoma that have not been treated with CAR T-cells before. It aims to see if the treatment is safe and works against tumors that have CD19 or CD20 proteins.
This trial tests a new treatment called LV009 for people with certain blood cancers (like leukemia or lymphoma) that have come back or not responded to standard therapy. It aims to see if the treatment is safe and effective.
This trial tests a new treatment called LV009, a type of CAR-T cell therapy, for people with certain blood cancers (like leukemia or lymphoma) that have CD19 on their cells. The therapy uses your own immune cells to fight the cancer.
This trial tests an investigational cell therapy called B019 for people with B-cell non-Hodgkin's lymphoma that has come back or not responded to treatment. The therapy targets cancer cells that have CD19 and/or CD22 on their surface, and the study aims to see if it is safe and effective.
This trial tests an investigational cell therapy that targets two markers (CD20 and CD19) on your lymphoma cells. It may be an option if your B-cell lymphoma has come back or not responded to prior treatments.
Hear when a new Non-Hodgkin Lymphoma (NHL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.